Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Waters Marks 25 Years in Ireland with €6 Million Clinical Diagnostics R&D Center Expansion in Wexford: https://mms.businesswire.com/media/20221007005094/en/1595143/5/LiamLeanneWaters.jpg
Waters Marks 25 Years in Ireland with €6 Million Clinical Diagnostics R&D Center Expansion in Wexford


Waters Corporation (NYSE: WAT) today announced a combined investment of up to €6 million with support from IDA Ireland to expand its operations in Drinagh, Wexford to fund research and development

Markteinführung des Dexcom G7 in Großbritannien, Irland, Deutschland, Österreich und Hongkong – Start des globalen Rollouts des weltweit leistungsstärksten Systems zur kontinuierlichen Blutzuckerüberwachung: https://mms.businesswire.com/media/20221004005387/de/1590800/5/Warriors_Ava_%26_Rebecca_Dexcom_G7%5B1%5D.jpg
Markteinführung des Dexcom G7 in Großbritannien, Irland, Deutschland, Österreich und Hongkong – Start des globalen Rollouts des weltweit leistungsstärksten Systems zur kontinuierlichen Blutzuckerüberwachung


DexCom, Inc. (Nasdaq: DXCM), der weltweit führende Anbieter von Systemen zur kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute die Einführung des Dexcom G7 Systems

Markteinführung des Dexcom G7 in Großbritannien, Irland, Deutschland, Österreich und Hongkong – Start des globalen Rollouts des weltweit leistungsstärksten Systems zur kontinuierlichen Blutzuckerüberwachung: https://mms.businesswire.com/media/20221004005387/de/1590800/5/Warriors_Ava_%26_Rebecca_Dexcom_G7%5B1%5D.jpg
Markteinführung des Dexcom G7 in Großbritannien, Irland, Deutschland, Österreich und Hongkong – Start des globalen Rollouts des weltweit leistungsstärksten Systems zur kontinuierlichen Blutzuckerüberwachung


DexCom, Inc. (Nasdaq: DXCM), der weltweit führende Anbieter von Systemen zur kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute die Einführung des Dexcom G7 Systems

Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System: https://mms.businesswire.com/media/20221004005386/en/1590800/5/Warriors_Ava_%26_Rebecca_Dexcom_G7%5B1%5D.jpg
Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System


DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System is now

Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System: https://mms.businesswire.com/media/20221004005386/en/1590800/5/Warriors_Ava_%26_Rebecca_Dexcom_G7%5B1%5D.jpg
Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System


DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System is now

ADDING MULTIMEDIA Humana significantly expands Medicare Advantage health plan offerings in 2023 with focus on greater value for members: https://mms.businesswire.com/media/20221001005004/en/1589832/5/AEP_Quote_-_George_Renaudin.jpg
ADDING MULTIMEDIA Humana significantly expands Medicare Advantage health plan offerings in 2023 with focus on greater value for members


Humana Inc. (NYSE: HUM) today released details of its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2023 – with a clear focus on benefits and support based on what its

Waters Extends Capabilities of Flagship TA Instruments Rheometer for Efficient and Repeatable Powder Analysis: https://mms.businesswire.com/media/20220929005711/en/1587282/5/DHR-Powder_6b-Flow-Samples_Overall.jpg
Waters Extends Capabilities of Flagship TA Instruments Rheometer for Efficient and Repeatable Powder Analysis


Waters Corporation (NYSE:WAT) today introduced new, innovative powder rheology tooling and software for its TA Instruments™ HR Rheometers allowing scientists to make preciseii, repeatable powder

EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
Henry Ford Health and Acadia Healthcare Break Ground on New Behavioral Health Hospital: https://mms.businesswire.com/media/20220927006047/en/1584747/5/AcadiaHealthcareHenryFordHealthGroundbreaking.jpg
Henry Ford Health and Acadia Healthcare Break Ground on New Behavioral Health Hospital


Henry Ford Health, one of the nation’s premier academic and integrated health systems, and Acadia Healthcare, the nation’s largest stand-alone behavioral healthcare company, broke ground today on a

Waters Announces Bay State’s First LEED-Certified Chemical Manufacturing Facility: https://mms.businesswire.com/media/20220926005707/en/1582828/5/DJI_0884_%281%29.jpg
Waters Announces Bay State’s First LEED-Certified Chemical Manufacturing Facility


Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, today announced its newly built Precision Chemical Manufacturing Facility in Taunton, Mass. has achieved LEED

EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
Acadia Healthcare Appoints Dr. Nasser Khan to Lead Its CTC Business: https://mms.businesswire.com/media/20220914005293/en/1571136/5/Kahn_photo.jpg
Acadia Healthcare Appoints Dr. Nasser Khan to Lead Its CTC Business


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Nasser Khan, M.D., as Operations Group President for its Comprehensive Treatment Center (CTC) business. Dr

DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
Humana Finalizes Launch of CenterWell Home Health: https://mms.businesswire.com/media/20220901005209/en/1558949/5/CenterWell_Home_Health_launch_map_FINAL_08.29.22.jpg
Humana Finalizes Launch of CenterWell Home Health


Humana Inc. (NYSE: HUM) has announced the completion of its initiative to rebrand the home health division of Kindred at Home (KAH) as CenterWell Home Health. With today’s announcement, CenterWell

DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
CenterWell Senior Primary Care to Open 9 Senior-Focused Care Centers in and Around Phoenix: https://mms.businesswire.com/media/20220825005486/en/1553629/5/CenterWell_Maryvale_staff.jpg
CenterWell Senior Primary Care to Open 9 Senior-Focused Care Centers in and Around Phoenix


CenterWell Senior Primary Care will open nine new senior-focused primary care centers in the Phoenix area through early 2023, marking the company’s debut in the Arizona market, giving local seniors

DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-Adhoc: Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
DGAP-Adhoc: Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
DGAP-Adhoc: Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems: https://mms.businesswire.com/media/20220810005669/en/1541099/5/355A9109.jpg
STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced its partnership with singer

DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303